ArticleJournal for immunotherapy of cancer2023
Single-cell sequencing on CD8
Abstract read
In one paragraph
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Characterization of persistent HPV-specific activated T cells in head and neck squamous cell carcinoma.Oncoimmunology · 2026Article
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Abundant CD8British journal of cancer · 2026Article
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.Cancer discovery · 2026Article
- Article
- Unraveling the multidimensional pleural ecosystem of lung cancer-associated malignant pleural effusion.Cancer cell international · 2026Review
- GITR activation potentiates anti-tumor immunity of tumor-infiltrating lymphocytes expanded from glioblastoma by rescuing exhaustion.Oncogene · 2026Article
- Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives.Clinical and experimental medicine · 2026Review
- Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade.Frontiers in immunology · 2026Review
- Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.Frontiers in oncology · 2026Article
- An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer.Oncoimmunology · 2025Article
- In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2025Article
- [Influence and Mechanism of Immunophenotyping on the Efficacy of Neoadjuvant Therapy in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Harnessing ferroptosis to transform glioblastoma therapy and surmount treatment resistance.Cell death discovery · 2025Review
- Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy.Translational lung cancer research · 2025Review
- High baseline PD-1+ CD8 T Cells and TIGIT+ CD8 T Cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2025Article
- The diversity of CD8Nature reviews. Immunology · 2025Review
- CD103Clinical and translational medicine · 2025Article
- Mechanisms of IGF1R signaling in type 2 diabetes-related neurodegeneration and therapeutic implications of exercise.European journal of medical research · 2025Article
- Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Hiroyasu Komuro *Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Shuichi Shinohara *Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yasunori FukushimaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Ayako Demachi-OkamuraDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Daisuke MuraokaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Katsuhiro MasagoPathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0003-3569-2978
Takuya MatsuiDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yusuke SugitaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yusuke TakahashiDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Reina NishidaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Chieko TakashimaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Takashi OhkiDepartment of Respiratory Surgery, Ichinomiya Nishi Hospital, Ichinomiya, Japan.
Yoshiki ShigematsuDepartment of Respiratory Surgery, Ichinomiya Nishi Hospital, Ichinomiya, Japan.
Fumiaki WatanabeDepartment of Thoracic Surgery, Mie Chuo Medical Center, Tsu, Japan.
Katsutoshi AdachiDepartment of Thoracic Surgery, Mie Chuo Medical Center, Tsu, Japan.
Takashi FukuyamaDivision of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan.
Hiroshi HamanaDepartment of Immunology, University of Toyama, Toyama, Japan.
Hiroyuki KishiDepartment of Immunology, University of Toyama, Toyama, Japan.
Daiki MiuraDrug Development Division, NEC Corporation, Minato-ku, Japan.
Yuki TanakaDrug Development Division, NEC Corporation, Minato-ku, Japan.
Kousuke OnoueDrug Development Division, NEC Corporation, Minato-ku, Japan.
Kazuhide OnoguchiDrug Development Division, NEC Corporation, Minato-ku, Japan.
Yoshiko YamashitaDrug Development Division, NEC Corporation, Minato-ku, Japan.
Richard StratfordNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Trevor ClancyNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Rui YamaguchiDivision of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Hiroaki KurodaDepartment of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Kiyoshi DoiDepartment of General Thoracic Surgery, Gifu University School of Medicine Graduate School of Medicine, Gifu, Japan.
Hisashi IwataDepartment of General Thoracic Surgery, Gifu University School of Medicine Graduate School of Medicine, Gifu, Japan h.matsushita@aichi-cc.jp ihisashi@gifu-u.ac.jp.
Hirokazu MatsushitaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan h.matsushita@aichi-cc.jp ihisashi@gifu-u.ac.jp.ORCID 0000-0001-9069-7160
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD8
methodsHigh throughput single-cell RNA sequencing and single-cell T-cell receptor (TCR) sequencing were performed on CD8
resultsA total of 6998 CD8
conclusionsOur approach focusing on T cells with an exhausted phenotype among CD8
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAntigens, NeoplasmCD8-Positive T-LymphocytesHumansLymphocytes, Tumor-InfiltratingReceptors, Antigen, T-CellSignal TransductionTestisAntigens, NeoplasmReceptors, Antigen, T-CellAntigens, NeoplasmCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingNon-Small Cell Lung Cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.